Compare IMVT & COMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMVT | COMP |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.8B |
| IPO Year | 2019 | 2021 |
| Metric | IMVT | COMP |
|---|---|---|
| Price | $28.29 | $7.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $31.22 | $11.80 |
| AVG Volume (30 Days) | 1.4M | ★ 14.1M |
| Earning Date | 05-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.74 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $6,961,600,000.00 |
| Revenue This Year | N/A | $90.43 |
| Revenue Next Year | N/A | $8.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 23.67 |
| 52 Week Low | $13.36 | $5.66 |
| 52 Week High | $30.09 | $13.96 |
| Indicator | IMVT | COMP |
|---|---|---|
| Relative Strength Index (RSI) | 59.48 | 49.36 |
| Support Level | $22.25 | $7.68 |
| Resistance Level | $29.25 | $8.30 |
| Average True Range (ATR) | 1.24 | 0.36 |
| MACD | 0.36 | 0.17 |
| Stochastic Oscillator | 72.73 | 71.97 |
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
Compass Inc provides an end-to-end platform that empowers residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service and other critical functionality, all custom-built for the real estate industry and enabling core brokerage services. Business operations are conducted in the United States and earn revenue domestically.